Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026

WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Detail	Information
Date	Friday, November 13, 2026
Time	10:00 a.m. Eastern Time
U.S. / Canada toll-free	1-877-877-1275
International	1-412-858-5202
Webcast	https://event.choruscall.com/mediaframe/webcast.html?webcastid=pyDsmcVf

Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call.

About Biofrontera Inc.

Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company’s products, which include Ameluz® as well as the RhodoLED® Lamps are used for the treatment of actinic keratosis, a common skin condition characterized by the growth of pre-cancerous skin lesions and, following U.S. Food and Drug Administration approval in September 2026, superficial basal cell carcinoma. For more information, visit www.biofrontera-us.com.

Investor Contact

Ben Shamsian
Lytham Partners
shamsian@lythampartners.com